Envestnet Asset Management Inc. Lowers Stake in ICU Medical, Inc. (NASDAQ:ICUI)

Envestnet Asset Management Inc. trimmed its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 1.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,735 shares of the medical instruments supplier’s stock after selling 355 shares during the period. Envestnet Asset Management Inc. owned approximately 0.08% of ICU Medical worth $2,907,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Harvest Fund Management Co. Ltd acquired a new position in ICU Medical during the 4th quarter worth about $33,000. Murphy & Mullick Capital Management Corp acquired a new stake in shares of ICU Medical during the fourth quarter worth about $52,000. Venturi Wealth Management LLC boosted its stake in shares of ICU Medical by 64.0% in the fourth quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier’s stock valued at $82,000 after purchasing an additional 206 shares during the period. Smartleaf Asset Management LLC grew its holdings in shares of ICU Medical by 166.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 907 shares of the medical instruments supplier’s stock valued at $140,000 after purchasing an additional 567 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in ICU Medical during the 4th quarter worth approximately $202,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical Price Performance

Shares of NASDAQ ICUI opened at $135.66 on Friday. The stock’s 50-day simple moving average is $143.81 and its 200-day simple moving average is $158.23. The firm has a market capitalization of $3.33 billion, a PE ratio of -29.68 and a beta of 0.86. ICU Medical, Inc. has a fifty-two week low of $94.19 and a fifty-two week high of $196.26. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. StockNews.com lowered ICU Medical from a “buy” rating to a “hold” rating in a research report on Thursday. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Tuesday, April 8th. KeyCorp lowered their price objective on ICU Medical from $209.00 to $191.00 and set an “overweight” rating for the company in a research report on Monday, April 21st. Finally, Raymond James set a $97.00 target price on shares of ICU Medical in a report on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, ICU Medical has a consensus rating of “Moderate Buy” and an average price target of $162.67.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.